Rebecca Feldman on Oncogenic Role of Caveolin-1 in Breast Cancer

Video

Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1 as potentially having an oncogenic role in breast cancer.

Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1, which could potentially have an oncogenic role in breast cancer.

In a recent study, researchers sought to determine whether caveolin-1 (CAV1) is a tumor suppressor or a proto-oncogene in patients with breast cancer. Due to known interactions with signaling molecules, it was investigated whether or not CAV1-positive breast cancers differ from CAV1-negative breast cancers.

CAV1 positivity was found to be significantly associated with triple-negative breast cancer (TNBC) status, which coincided with earlier studies. A further analysis examined patients with CAV1-positive TNBC versus CAV1-negative TNBC. EGFR was found to be upregulated in patients with CAV1-positivity by protein expression. Additionally, overexpression of PDGFRA, ERCC1, and TLE3 were also found in CAV1-positive patients.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Minesh Mehta, MD
Ruben Olivares, MD